4 OPPENHEIMER ST., 11TH FLOOR, REHOVOT, L3
Extraordinary General Meeting to be held on July 29, 2026
Announces $2.6 Million Private Placement
Reports 2026 First Quarter Financial Results and Provides Corporate Update
Letter to Shareholders Collaborations
Receives Nasdaq Notification Regarding Minimum Bid Requirement
Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
Annual and Transition Report of Foreign Private Issuers
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload